Heart of Orléans BIA

Ontario Expanding Booster Eligibility to More Ontarians

Eligibility Will Expand Gradually Based on Age and Risk to Provide Extra Layer of Protection Against the Delta Variant

The Ontario government, in consultation with the Chief Medical Officer of Health, is expanding eligibility for booster doses of the COVID-19 vaccine to additional groups of high-risk individuals starting November 6, 2021, providing them with an extra layer of protection against the Delta variant. Over the coming months, Ontario is also prepared to gradually roll out booster doses to all Ontarians aged 12 and over.

While the province continues to report one of the lowest rates of active cases in the country and continues to make steady progress in vaccinating more individuals, offering the extra layer of protection provided by a booster dose will contribute to the fight against COVID-19.

Based on the recommendation of the Chief Medical Officer of Health and in alignment with the National Advisory Committee on Immunization’s (NACI) recent recommendation, the province will begin offering booster doses of the COVID-19 vaccine to the following vulnerable populations if at least six months have passed since their last dose:

  • Individuals aged 70 and over (born in 1951 or earlier);
  • Health care workers and designated essential caregivers in congregate settings (including long-term care home and retirement home staff and designated caregivers);
  • Individuals who received a complete series of a viral vector vaccine (two doses of the AstraZeneca vaccine or one dose of the Janssen vaccine); and
  • First Nation, Inuit and Métis adults and their non-Indigenous household members.

Booster doses are being offered to these groups based on evidence of gradual waning immunity six months after receiving their second dose and a higher risk of severe illness from COVID-19.

Starting on Saturday, November 6 at 8:00 a.m., eligible individuals will be able to book their booster dose appointment through the COVID-19 vaccination portal or by calling the Provincial Vaccine Contact Centre, directly through public health units that use their own booking systems, through Indigenous-led vaccination clinics, select pharmacies, and primary care settings. Hospital-based health care workers are encouraged to reach out to their hospital employer to get vaccinated directly through their hospital’s vaccination program.

Locations and timing for booster doses may vary by public health unit based on local planning and considerations.

In addition, Ontario is once again supporting northern and remote fly in First Nation communities by launching Operation Remote Immunity 3.0, this time through the co-development of plans with Health Canada’s First Nations and Inuit Health Branch, to support Sioux Lookout First Nations Health Authority and Weeneebayko Area Health Authority, First Nation health organizations, to administer booster doses in their communities with transportation and vaccine supply assistance from Ornge and local public health units.

While the COVID-19 vaccine is highly effective, the province is prepared to expand eligibility for a booster dose to all Ontarians over time. Based on Ontario’s COVID-19 vaccination rollout for first and second doses, expansion of eligibility for booster doses will be based on age and risk, with an interval of six to eight months from the second dose.

During the height of Ontario’s COVID-19 vaccine rollout, a large population of Ontarians received their first and second doses at a longer interval than indicated on the product monograph. This longer interval has now been shown to improve duration of protection, and the National Advisory Committee on Immunization now recommends an optimal interval of eight weeks between first and second doses.

COVID-19 vaccine eligibility for children aged five to 11 is subject to Health Canada approval. Ontario is working with public health units across the province to prepare to vaccinate children aged five to 11. The Pfizer COVID-19 vaccine for children aged five to 11 is a distinct formulation at a lower dose and supply of vaccine that will be rolled out in parallel to booster doses.